Mario Cazzola

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2016-2023
Publications (10 Years): 97

Top Topics

Muscular Dystrophy

Combination Therapy

Systematic Review

Top Venues

Expert review of respiratory medicine

Expert opinion on pharmacotherapy

Expert opinion on drug metabolism & toxicology

Expert opinion on investigational drugs

This page only lists publications with an associated author ORCID identifier.

Publications

Mario Cazzola, Rogliani Paola, Josuel Ora, Luigino Calzetta, Davide Lauro, Maria Gabriella Matera
Hyperglycaemia and Chronic Obstructive Pulmonary Disease. Diagnostics (Basel, Switzerland) 13 (21) (2023)
Maria Gabriella Matera, Josuel Ora, Luigino Calzetta, Rogliani Paola, Mario Cazzola
Investigational anti IL-13 asthma treatments: a 2023 update. Expert opinion on investigational drugs (2023)
Daiana Stolz, Maria Gabriella Matera, Rogliani Paola, Maarten van den Berge, Eleni Papakonstantinou, Reinoud Gosens, Dave Singh, Nicola Hanania, Mario Cazzola, Anke-Hilse Maitland-van der Zee, Laura Fregonese, Alexander G Mathioudakis, Jorgen Vestbo, Maia Rukhadze, Clive P Page
Current and future developments in the pharmacology of asthma and COPD: ERS seminar, Naples 2022. Breathe (Sheffield, England) 19 (2) (2023)
Mario Cazzola, Clive P Page, Maria Gabriella Matera, Rogliani Paola, Nicola A Hanania
Revisiting Asthma Pharmacotherapy: Where Do We Stand and Where Do We Want to Go? The European respiratory journal (2023)
Luigino Calzetta, Clive Page, Maria Gabriella Matera, Mario Cazzola, Rogliani Paola
Use of human airway smooth muscle in vitro and ex vivo to investigate drugs for the treatment of chronic obstructive respiratory disorders. British journal of pharmacology (2023)
Mario Cazzola, Paola Rogliani, Peter J Barnes, Francesco Blasi, Bartolome R Celli, Nicola A Hanania, Fernando J Martinez, Bruce E Miller, Marc Miravitlles, Clive P Page, Ruth Tal-Singer, Maria Gabriella Matera
Updating the ATS/ERS Task Force Report on Outcomes for COPD Pharmacological Trials. American journal of respiratory and critical care medicine (2023)
Luigino Calzetta, Mario Cazzola, Paola Rogliani
Pharmacological Interpretation of the Efficacy of Ensifentrine in COPD: Insights from ENHANCE Trials. American journal of respiratory and critical care medicine (2023)
Mario Cazzola, Clive Peter Page, Luigino Calzetta, Dave Singh, Paola Rogliani, Maria Gabriella Matera
What role will ensifentrine play in the future treatment of chronic obstructive pulmonary disease patients? Implications from recent clinical trials. Immunotherapy (2023)
Mario Cazzola, Paola Rogliani, Josuel Ora, Luigino Calzetta, Maria Gabriella Matera
Cardiovascular diseases or type 2 diabetes mellitus and chronic airway diseases: mutual pharmacological interferences. Therapeutic advances in chronic disease 14 (2023)
Daiana Stolz, Maria Gabriella Matera, Rogliani Paola, Maarten van den Berge, Eleni Papakonstantinou, Reinoud Gosens, Dave Singh, Nicola Hanania, Mario Cazzola, Anke-Hilse Maitland-van der Zee, Laura Fregonese, Alexander G Mathioudakis, Jorgen Vestbo, Maia Rukhadze, Clive P Page
Current and future developments in the pharmacology of asthma and COPD: ERS seminar, Naples 2022. Breathe (Sheffield, England) 19 (2) (2023)
Maria Gabriella Matera, Barbara Rinaldi, Luigino Calzetta, Paola Rogliani, Mario Cazzola
Advances in adrenergic receptors for the treatment of chronic obstructive pulmonary disease: 2023 update. Expert opinion on pharmacotherapy (2023)
Mario Cazzola, Luigino Calzetta, Barbara Rinaldi, Vito De Novellis, Rogliani Paola, Maria Gabriella Matera
Clinical characteristics, treatment patterns and adherence in patients with asthma on multiple inhaler triple therapy: a review of findings. Expert review of respiratory medicine (2023)
Maria Gabriella Matera, Josuel Ora, Luigino Calzetta, Rogliani Paola, Mario Cazzola
Investigational anti IL-13 asthma treatments: a 2023 update. Expert opinion on investigational drugs (2023)
Mario Cazzola, Luigino Calzetta, Barbara Rinaldi, Vito De Novellis, Rogliani Paola, Maria Gabriella Matera
Clinical characteristics, treatment patterns and adherence in patients with asthma on multiple inhaler triple therapy: a review of findings. Expert review of respiratory medicine 16 (11-12) (2023)
Mario Cazzola, Rogliani Paola, Francesco Blasi
Can Treatable Traits Be the Approach to Addressing the Complexity and Heterogeneity of COPD? International journal of chronic obstructive pulmonary disease 18 (2023)
Gian Marco Manzetti, Josuel Ora, Arianna Sepiacci, Mario Cazzola, Rogliani Paola, Luigino Calzetta
Clinically Important Deterioration (CID) and Ageing in COPD: A Systematic Review and Meta-Regression Analysis According to PRISMA Statement. International journal of chronic obstructive pulmonary disease 18 (2023)
Maria Gabriella Matera, Rogliani Paola, Giuseppe Novelli, Mario Cazzola
The impact of genomic variants on patient response to inhaled bronchodilators: a comprehensive update. Expert opinion on drug metabolism & toxicology (2023)
Mario Cazzola, Luigino Calzetta, Barbara Rinaldi, Vito De Novellis, Rogliani Paola, Maria Gabriella Matera
Clinical characteristics, treatment patterns and adherence in patients with asthma on multiple inhaler triple therapy: a review of findings. Expert review of respiratory medicine 16 (11-12) (2023)
Mario Cazzola, Paola Rogliani, Maria Gabriella Matera
Might It Be Appropriate to Anticipate the Use of Long-Acting Muscarinic Antagonists in Asthma? Drugs (2023)
Maria Gabriella Matera, Paola Rogliani, Josuel Ora, Luigino Calzetta, Mario Cazzola
A comprehensive overview of investigational elastase inhibitors for the treatment of acute respiratory distress syndrome. Expert opinion on investigational drugs (2023)
Mario Cazzola, Nicola A Hanania, Clive P Page, Maria Gabriella Matera
Novel Anti-Inflammatory Approaches to COPD. International journal of chronic obstructive pulmonary disease 18 (2023)
Maria Gabriella Matera, Nicola A Hanania, Mauro Maniscalco, Mario Cazzola
Pharmacotherapies in Older Adults with COPD: Challenges and Opportunities. Drugs & aging (2023)
Daiana Stolz, Maria Gabriella Matera, Rogliani Paola, Maarten van den Berge, Eleni Papakonstantinou, Reinoud Gosens, Dave Singh, Nicola Hanania, Mario Cazzola, Anke-Hilse Maitland-van der Zee, Laura Fregonese, Alexander G Mathioudakis, Jorgen Vestbo, Maia Rukhadze, Clive P Page
Current and future developments in the pharmacology of asthma and COPD: ERS seminar, Naples 2022. Breathe (Sheffield, England) 19 (2) (2023)
Maria Gabriella Matera, Luigino Calzetta, Barbara Rinaldi, Mario Cazzola, Rogliani Paola
Strategies for overcoming the biological barriers associated with the administration of inhaled monoclonal antibodies for lung diseases. Expert opinion on drug delivery (2023)
Mario Cazzola, Luigino Calzetta, Barbara Rinaldi, Vito De Novellis, Rogliani Paola, Maria Gabriella Matera
Clinical characteristics, treatment patterns and adherence in patients with asthma on multiple inhaler triple therapy: a review of findings. Expert review of respiratory medicine (2023)
Maria Gabriella Matera, Luigino Calzetta, Mario Cazzola, Josuel Ora, Rogliani Paola
Biologic therapies for chronic obstructive pulmonary disease. Expert opinion on biological therapy 23 (2) (2022)
Luigino Calzetta, Marina Aiello, Annalisa Frizzelli, Francesca Camardelli, Mario Cazzola, Rogliani Paola, Alfredo Chetta
Stem Cell-Based Regenerative Therapy and Derived Products in COPD: A Systematic Review and Meta-Analysis. Cells 11 (11) (2022)
Maria Gabriella Matera, Luigino Calzetta, Mario Cazzola, Josuel Ora, Rogliani Paola
Biologic therapies for chronic obstructive pulmonary disease. Expert opinion on biological therapy 23 (2) (2022)
Andrea Bianco, Stefano Conte, Domenica Francesca Mariniello, Valentino Allocca, Maria Gabriella Matera, Vito D'Agnano, Luigi Lanata, Mario Cazzola, Fabio Perrotta
Mucolytic and Antioxidant Properties of Carbocysteine as a Strategy in COVID-19 Therapy. Life (Basel, Switzerland) 12 (11) (2022)
Miguel Angel Martinez-Garcia, Fernando Santamaría-Martos, Alberto García-Ortega, Maria Gabriella Matera, Rogliani Paola, Mario Cazzola
Inhaled Corticosteroids in Adults with Non-cystic Fibrosis Bronchiectasis: From Bench to Bedside. A Narrative Review. Drugs 82 (14) (2022)
Maria Gabriella Matera, Barbara Rinaldi, Vito de Novellis, Rogliani Paola, Mario Cazzola
Current and emerging treatment modalities for bacterial rhinosinusitis in adults: a comprehensive review. Expert opinion on pharmacotherapy 23 (18) (2022)
Maria Gabriella Matera, Luigino Calzetta, Mario Cazzola, Josuel Ora, Rogliani Paola
Biologic therapies for chronic obstructive pulmonary disease. Expert opinion on biological therapy (2022)
Mario Cazzola, Josuel Ora, Luigino Calzetta, Rogliani Paola, Maria Gabriella Matera
Advances in inhaled corticosteroids for the treatment of chronic obstructive pulmonary disease: what is their value today? Expert opinion on pharmacotherapy 23 (8) (2022)
Mario Cazzola, Clive Peter Page, Rogliani Paola, Luigino Calzetta, Maria Gabriella Matera
Dual bronchodilation for the treatment of COPD: From bench to bedside. British journal of clinical pharmacology 88 (8) (2022)
Mario Cazzola, Rogliani Paola, Silvio Naviglio, Luigino Calzetta, Maria Gabriella Matera
An update on the currently available and emerging synthetic pharmacotherapy for uncontrolled asthma. Expert opinion on pharmacotherapy 23 (10) (2022)
Peter M A Calverley, Alberto Papi, Clive Peter Page, Rogliani Paola, Roberto Walter Dal Negro, Mario Cazzola, Arrigo Francesco Giuseppe Cicero, Jadwiga A Wedzicha
The Effect of Maintenance Treatment with Erdosteine on Exacerbation Treatment and Health Status in Patients with COPD: A Post-Hoc Analysis of the RESTORE Dataset. International journal of chronic obstructive pulmonary disease 17 (2022)
Maria Gabriella Matera, Barbara Rinaldi, Carmela Belardo, Mario Cazzola
Pharmacotherapy of LAMA/LABA inhaled therapy combinations for chronic obstructive pulmonary disease: a clinical overview. Expert review of clinical pharmacology 15 (11) (2022)
Mario Cazzola, Rogliani Paola, Luigino Calzetta, Josuel Ora, Maria Gabriella Matera
A single inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol for the treatment of COPD. Expert review of clinical pharmacology 15 (3) (2022)
Rogliani Paola, Josuel Ora, Francesco Cavalli, Mario Cazzola, Luigino Calzetta
Comparing the Efficacy and Safety Profile of Triple Fixed-Dose Combinations in COPD: A Meta-Analysis and IBiS Score. Journal of clinical medicine 11 (15) (2022)
Rogliani Paola, Francesco Cavalli, Alfredo Chetta, Mario Cazzola, Luigino Calzetta
Potential Drawbacks of ICS/LABA/LAMA Triple Fixed-Dose Combination Therapy in the Treatment of Asthma: A Quantitative Synthesis of Safety Profile. Journal of asthma and allergy 15 (2022)
Mario Cazzola, Rogliani Paola, Rossella Laitano, Luigino Calzetta, Maria Gabriella Matera
Beyond Dual Bronchodilation - Triple Therapy, When and Why. International journal of chronic obstructive pulmonary disease 17 (2022)
Maria Gabriella Matera, Luigino Calzetta, Mario Cazzola, Josuel Ora, Rogliani Paola
Biologic therapies for chronic obstructive pulmonary disease. Expert opinion on biological therapy (2022)
Maria Gabriella Matera, Luigino Calzetta, Mario Cazzola, Josuel Ora, Rogliani Paola
Biologic therapies for chronic obstructive pulmonary disease. Expert opinion on biological therapy 23 (2) (2022)
Maria Gabriella Matera, Luigino Calzetta, Josuel Ora, Rogliani Paola, Mario Cazzola
Pharmacokinetic/pharmacodynamic approaches to drug delivery design for inhalation drugs. Expert opinion on drug delivery 18 (7) (2021)
Maria Gabriella Matera, Josuel Ora, Francesco Cavalli, Rogliani Paola, Mario Cazzola
New Avenues for Phosphodiesterase Inhibitors in Asthma. Journal of experimental pharmacology 13 (2021)
Mario Cazzola, Josuel Ora, Francesco Cavalli, Rogliani Paola, Maria Gabriella Matera
An Overview of the Safety and Efficacy of Monoclonal Antibodies for the Chronic Obstructive Pulmonary Disease. Biologics : targets & therapy 15 (2021)
Mario Cazzola, Paola Rogliani, Sundeep Santosh Salvi, Josuel Ora, Maria Gabriella Matera
Use of Thiols in the Treatment of COVID-19: Current Evidence. Lung 199 (4) (2021)
Mario Cazzola, Luigino Calzetta, Maria Gabriella Matera
Long-acting muscarinic antagonists and small airways in asthma: Which link? Allergy 76 (7) (2021)
Maria Gabriella Matera, Luigino Calzetta, Rosa Annibale, Francesco Russo, Mario Cazzola
Classes of drugs that target the cellular components of inflammation under clinical development for COPD. Expert review of clinical pharmacology 14 (8) (2021)
Miguel Angel Martinez-Garcia, Fernando Santamaría-Martos, Alberto García-Ortega, Maria Gabriella Matera, Rogliani Paola, Mario Cazzola
Rationale and Clinical Use of Bronchodilators in Adults with Bronchiectasis. Drugs (2021)
Mario Cazzola, Josuel Ora, Francesco Cavalli, Paola Rogliani, Maria Gabriella Matera
Treatable Mechanisms in Asthma. Molecular diagnosis & therapy 25 (2) (2021)
Mario Cazzola, Maria Gabriella Matera, Rogliani Paola, Luigino Calzetta, Josuel Ora
Step-up and step-down approaches in the treatment of asthma. Expert review of respiratory medicine 15 (9) (2021)
Maria Gabriella Matera, Francesco Imperatore, Rosa Annibale, Mario Cazzola
Advances in the Pharmacological Management of Pediatric Acute Respiratory Distress Syndrome. Expert opinion on pharmacotherapy (2021)
Mario Cazzola, Josuel Ora, Andrea Bianco, Rogliani Paola, Maria Gabriella Matera
Management of COPD patients during COVID: difficulties and experiences. Expert review of respiratory medicine 15 (8) (2021)
Mario Cazzola, Clive Page, Paola Rogliani, Luigino Calzetta, Maria Gabriella Matera
Multifaceted Beneficial Effects of Erdosteine: More than a Mucolytic Agent. Drugs 80 (17) (2021)
Maria Gabriella Matera, Josuel Ora, Luigino Calzetta, Rogliani Paola, Mario Cazzola
Sex differences in COPD management. Expert review of clinical pharmacology 14 (3) (2021)
Luigino Calzetta, Beatrice Ludovica Ritondo, Patrizia de Marco, Mario Cazzola, Rogliani Paola
Evaluating triple ICS/LABA/LAMA therapies for COPD patients: a network meta-analysis of ETHOS, KRONOS, IMPACT, and TRILOGY studies. Expert review of respiratory medicine 15 (1) (2020)
Josuel Ora, Angelo Coppola, Mario Cazzola, Luigino Calzetta, Rogliani Paola
Long-Acting Muscarinic Antagonists Under Investigational to Treat Chronic Obstructive Pulmonary Disease. Journal of experimental pharmacology 12 (2020)
Beatrice Ludovica Ritondo, Ermanno Puxeddu, Luigino Calzetta, Mario Cazzola, Rogliani Paola
Efficacy and safety of triple combination therapy for treating chronic obstructive pulmonary disease: an expert review. Expert opinion on pharmacotherapy 22 (5) (2020)
Luigino Calzetta, Beatrice Ludovica Ritondo, Maria Gabriella Matera, Gabriella Pezzuto, Mario Cazzola, Paola Rogliani
Investigational treatments in phase I and II clinical trials: a systematic review in chronic obstructive pulmonary disease (COPD). Expert opinion on investigational drugs 29 (7) (2020)
Nicola Scichilone, Peter John Barnes, Salvatore Battaglia, Alida Benfante, Robert Brown, Giorgio Walter Canonica, Gaetano Caramori, Mario Cazzola, Stefano Centanni, Antonella Cianferoni, Angelo Corsico, Giuseppe De Carlo, Federico Raimondi, Mina Gaga, Catherine Hawrylowicz, Enrico Heffler, Maria Gabriella Matera, Andrea Matucci, Pierluigi Paggiaro, Alberto Papi, Todor A Popov, Rogliani Paola, Pierachille Santus, Paolo Solidoro, Alkis Togias, Louis-Philippe Boulet
The Hidden Burden of Severe Asthma: From Patient Perspective to New Opportunities for Clinicians. Journal of clinical medicine 9 (8) (2020)
Filippo Scialo, Aurora Daniele, Felice Amato, Lucio Pastore, Maria Gabriella Matera, Mario Cazzola, Giuseppe Castaldo, Andrea Bianco
ACE2: The Major Cell Entry Receptor for SARS-CoV-2. Lung 198 (6) (2020)
Maria Gabriella Matera, Carmela Belardo, Michele Rinaldi, Barbara Rinaldi, Mario Cazzola
Emerging muscarinic receptor antagonists for the treatment of asthma. Expert opinion on emerging drugs 25 (2) (2020)
Maria Gabriella Matera, Carmela Belardo, Michele Rinaldi, Barbara Rinaldi, Mario Cazzola
New perspectives on the role of muscarinic antagonists in asthma therapy. Expert review of respiratory medicine 14 (8) (2020)
Maria Gabriella Matera, Paola Rogliani, Andrea Bianco, Mario Cazzola
Pharmacological management of adult patients with acute respiratory distress syndrome. Expert opinion on pharmacotherapy 21 (17) (2020)
Rogliani Paola, Beatrice Ludovica Ritondo, Ermanno Puxeddu, Gloria Pane, Mario Cazzola, Luigino Calzetta
Experimental Glucocorticoid Receptor Agonists for the Treatment of Asthma: A Systematic Review. Journal of experimental pharmacology 12 (2020)
Josuel Ora, Luigino Calzetta, Maria Gabriella Matera, Mario Cazzola, Rogliani Paola
Advances with glucocorticoids in the treatment of asthma: state of the art. Expert opinion on pharmacotherapy 21 (18) (2020)
Luigino Calzetta, Beatrice Ludovica Ritondo, Maria Gabriella Matera, Mario Cazzola, Paola Rogliani
Evaluation of fluticasone propionate/salmeterol for the treatment of COPD: a systematic review. Expert review of respiratory medicine 14 (6) (2020)
Rogliani Paola, Beatrice Ludovica Ritondo, Mariachiara Gabriele, Mario Cazzola, Luigino Calzetta
Optimizing de-escalation of inhaled corticosteroids in COPD: a systematic review of real-world findings. Expert review of clinical pharmacology 13 (9) (2020)
Luigino Calzetta, Maria Gabriella Matera, Paola Rogliani, Mario Cazzola
The role of triple therapy in the management of COPD. Expert review of clinical pharmacology 13 (8) (2020)
Maria Gabriella Matera, Barbara Rinaldi, Carmela Berardo, Michele Rinaldi, Mario Cazzola
A review of the pharmacokinetics of M3 muscarinic receptor antagonists used for the treatment of asthma. Expert opinion on drug metabolism & toxicology 16 (2) (2020)
Mario Cazzola, Francesco Cavalli, Omar S Usmani, Paola Rogliani
Advances in pulmonary drug delivery devices for the treatment of chronic obstructive pulmonary disease. Expert opinion on drug delivery 17 (5) (2020)
Mario Cazzola, Rogliani Paola, Luigino Calzetta, Maria Gabriella Matera
Pharmacogenomic Response of Inhaled Corticosteroids for the Treatment of Asthma: Considerations for Therapy. Pharmacogenomics and personalized medicine 13 (2020)
Paola Rogliani, Beatrice Ludovica Ritondo, Bartolomeo Zerillo, Mario Cazzola, Maria Gabriella Matera, Luigino Calzetta
Adding a Second Bronchodilator in COPD: A Meta-Analysis on the Risk of Specific Cardiovascular Serious Adverse Events of Tiotropium/Olodaterol Fixed-Dose Combination. COPD 17 (2) (2020)
Mario Cazzola, Paola Rogliani, Daiana Stolz, Maria Gabriella Matera
Pharmacological treatment and current controversies in COPD. F1000Research 8 (2019)
Rogliani Paola, Luigino Calzetta, Maria Gabriella Matera, Nicola di Daniele, Andrea Girolami, Mario Cazzola, Josuel Ora
Inhaled therapies and cardiovascular risk in patients with chronic obstructive pulmonary disease. Expert opinion on pharmacotherapy 20 (6) (2019)
Peter Ma Calverley, Clive Peter Page, Roberto W Dal Negro, Giovanni Fontana, Mario Cazzola, Arrigo F Cicero, Edoardo Pozzi, Jadwiga A Wedzicha
Effect of Erdosteine on COPD Exacerbations in COPD Patients with Moderate Airflow Limitation. International journal of chronic obstructive pulmonary disease 14 (2019)
Mario Cazzola, Ermanno Puxeddu, Maria Gabriella Matera, Paola Rogliani
A potential role of triple therapy for asthma patients. Expert review of respiratory medicine 13 (11) (2019)
Mario Cazzola, Luigino Calzetta, Paola Rogliani, Maria Gabriella Matera
Ensifentrine (RPL554): an investigational PDE3/4 inhibitor for the treatment of COPD. Expert opinion on investigational drugs 28 (10) (2019)
Maria Gabriella Matera, Luigino Calzetta, Ermanno Puxeddu, Paola Rogliani, Mario Cazzola
A safety comparison of LABA+LAMA vs LABA+ICS combination therapy for COPD. Expert opinion on drug safety 17 (5) (2018)
Alexandru Corlateanu, Serghei Covantsev, Alexander G Mathioudakis, Victor Botnaru, Mario Cazzola, Nikolaos Siafakas
Chronic Obstructive Pulmonary Disease and Stroke. COPD 15 (4) (2018)
Marco Mantero, Paola Rogliani, Mario Cazzola, Francesco Blasi, Marta Di Pasquale
Emerging antibacterial and antiviral drugs for treating respiratory tract infections. Expert opinion on emerging drugs 23 (3) (2018)
Mario Cazzola, Maria Gakriella Matera, Paola Rogliani, Luigino Calzetta
Senolytic drugs in respiratory medicine: is it an appropriate therapeutic approach? Expert opinion on investigational drugs 27 (7) (2018)
Luigino Calzetta, Maria Gabriella Matera, Paola Rogliani, Mario Cazzola
Multifaceted activity of N-acetyl-l-cysteine in chronic obstructive pulmonary disease. Expert review of respiratory medicine 12 (8) (2018)
Luigino Calzetta, Maria Gabriella Matera, Rogliani Paola, Mario Cazzola
Dual LABA/LAMA bronchodilators in chronic obstructive pulmonary disease: why, when, and how. Expert review of respiratory medicine 12 (4) (2018)
Mario Cazzola, Luigino Calzetta, Maria Gabriella Matera, Nicola A Hanania, Paola Rogliani
How does race/ethnicity influence pharmacological response to asthma therapies? Expert opinion on drug metabolism & toxicology 14 (4) (2018)
Maria Gabriella Matera, Paola Rogliani, Josuel Ora, Mario Cazzola
Current pharmacotherapeutic options for pediatric lower respiratory tract infections with a focus on antimicrobial agents. Expert opinion on pharmacotherapy 19 (18) (2018)
Maria Gabriella Matera, Barbara Rinaldi, Clive Peter Page, Paola Rogliani, Mario Cazzola
Pharmacokinetic considerations concerning the use of bronchodilators in the treatment of chronic obstructive pulmonary disease. Expert opinion on drug metabolism & toxicology 14 (10) (2018)
Rogliani Paola, Josuel Ora, Maria Gabriella Matera, Mario Cazzola, Luigino Calzetta
The safety of dual bronchodilation on cardiovascular serious adverse events in COPD. Expert opinion on drug safety 17 (6) (2018)
Mario Cazzola, Maria Gabriella Matera, Francesca Levi-Schaffer, Paola Rogliani
Safety of humanized monoclonal antibodies against IL-5 in asthma: focus on reslizumab. Expert opinion on drug safety 17 (4) (2018)
Mario Cazzola, Rogliani Paola, Luigino Calzetta, Nicola A Hanania, Maria Gabriella Matera
Impact of Mucolytic Agents on COPD Exacerbations: A Pair-wise and Network Meta-analysis. COPD 14 (5) (2017)
Maria Gabriella Matera, Barbara Rinaldi, Luigino Calzetta, Mario Cazzola
Pharmacogenetic and pharmacogenomic considerations of asthma treatment. Expert opinion on drug metabolism & toxicology 13 (11) (2017)
Luigino Calzetta, Rogliani Paola, Maurizio Mattei, Pietro Alfonsi, Giuseppe Cito, Elena Pistocchini, Mario Cazzola, Maria Gabriella Matera
Pharmacological characterization of the interaction between tiotropium and olodaterol administered at 5:5 concentration-ratio in equine bronchi. COPD 14 (5) (2017)
Maria Gabriella Matera, Luigino Calzetta, Barbara Rinaldi, Mario Cazzola
Pharmacokinetic/pharmacodynamic drug evaluation of benralizumab for the treatment of asthma. Expert opinion on drug metabolism & toxicology 13 (9) (2017)
Mario Cazzola, Paola Rogliani, Ermanno Puxeddu, Josuel Ora, Maria Gabriella Matera
An overview of the current management of chronic obstructive pulmonary disease: can we go beyond the GOLD recommendations? Expert review of respiratory medicine 12 (1) (2017)
Maria Gabriella Matera, Paola Rogliani, Luigino Calzetta, Mario Cazzola
Pharmacokinetic/pharmacodynamic profile of reslizumab in asthma. Expert opinion on drug metabolism & toxicology 14 (2) (2017)
Paola Rogliani, Ermanno Puxeddu, Chiara Ciaprini, Josuel Ora, Angelo Onorato, Gabriella Pezzuto, Luigino Calzetta, Mario Cazzola
The Time Course of Pulmonary Function Tests in COPD Patients with Different Levels of Blood Eosinophils. BioMed research international 2016 (2016)